Application Sponsors
Marketing Status
Application Products
001 | TABLET;ORAL-28 | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | 0 | TRI-ESTARYLLA | ETHINYL ESTRADIOL; NORGESTIMATE |
FDA Submissions
| ORIG | 1 | AP | 2013-01-30 | |
LABELING; Labeling | SUPPL | 3 | AP | 2015-08-25 | STANDARD |
LABELING; Labeling | SUPPL | 4 | AP | 2015-08-25 | STANDARD |
LABELING; Labeling | SUPPL | 6 | AP | 2022-02-03 | STANDARD |
LABELING; Labeling | SUPPL | 10 | AP | 2022-04-29 | STANDARD |
Submissions Property Types
ORIG | 1 | Null | 7 |
SUPPL | 3 | Null | 15 |
SUPPL | 4 | Null | 15 |
SUPPL | 6 | Null | 15 |
SUPPL | 10 | Null | 15 |
TE Codes
CDER Filings
XIROMED
cder:Array
(
[0] => Array
(
[ApplNo] => 90793
[companyName] => XIROMED
[docInserts] => ["",""]
[products] => [{"drugName":"TRI-ESTARYLLA","activeIngredients":"ETHINYL ESTRADIOL; NORGESTIMATE","strength":"0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG","dosageForm":"TABLET;ORAL-28","marketingStatus":"Prescription","te":"","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"TRI-ESTARYLLA","submission":"ETHINYL ESTRADIOL; NORGESTIMATE","actionType":"0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG","submissionClassification":"TABLET;ORAL-28","reviewPriority":"Prescription","inserts":"[]","notes":">No"}]
[supplements] =>
[actionDate] => 1969-12-31
)
)